These target the anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) and the anti-programmed cell death protein/protein ligand 1 (anti-PD-1/PD-L1) with antibodies and are being used for the treatment of melanoma, lung cancer, renal cell carcinoma and head and neck tumors [13–16]. The gene discussed is CTLA4; the disease is lung carcinoma.